Tramadol ER
Treatment for Chronic PainBiovail Updates Status of NDA for Tramadol ER
TORONTO, March 30, 2005 - Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that it has received comments from the United States Food and Drug Administration (FDA) with regard to its New Drug Application (NDA) for Tramadol ER, an extended-release, once-daily formulation of tramadol hydrochloride.
The FDA has acknowledged that Biovail's Complete Response to the Tramadol ER Approvable Letter is a Class 2 response, which is therefore subject to a six-month review. The FDA has also advised that, upon preliminary review, it is of the opinion that additional clinical trial data will be required. Biovail's view is that the clinical data contained within the original NDA and the March 2005 Complete Response fully support 505(b)(2) filing requirements, and the Company is considering a number of options. Biovail expects to meet with the FDA to discuss these options promptly. In the meantime, however, Biovail will immediately undertake a clinical program to address the FDA's comments. Biovail anticipates the submission of new clinical data in late 2005 or early 2006. Biovail believes that a new six-month review period would then be initiated.
Biovail's original application was submitted December 31, 2003 under provisions of Section 505(b)(2) of the Food, Drug and Cosmetic Act. The application included clinical and safety data obtained from four original adequate and well-controlled trials involving more than 3,000 patients who received doses of up to 400mg of Tramadol ER once daily. The application also included 12 definitive and five supportive pharmacokinetic studies which demonstrated that once-daily dosing of Tramadol ER delivers the equivalent amount of drug as Ultram(R) (tramadol hydrochloride tablets) given three times (TID) or four times (QID) per day.
In October 2004, Biovail's NDA for Tramadol ER received an Approvable Letter from the FDA. In March 2005, Biovail submitted a Complete Response to the FDA, which included a significant amount of statistical analyses, but no new clinical data. The response also addressed other items raised in the Approvable Letter, including discontinuation rates of clinical-trial participants (dropouts), which are common in pain trials, and previously well documented in studies involving tramadol.
About Biovail Corporation
Biovail Corporation is an international full-service pharmaceutical
company, engaged in the formulation, clinical testing,
registration, manufacture, sale and promotion of pharmaceutical
products utilizing advanced drug-delivery technologies.
Related Articles:
Tramadol ER Biovail Corporation - Treatment for Chronic Pain - September 8, 2005
Biovail's Ralivia ER Receives Approvable Letter From FDA - November 1, 2004
Biovail NDA For Ralivia ER -- Tramadol Extended Release Tablets -- Accepted for Review - February 26, 2004
New Drug Applications Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
